my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
12-17-2007: Pronova BioPharma ASA announced that it has entered into a worldwide licence and development agreement with FMC Corporation to develop products using a novel capsule technology.
The proprietary alginate-based capsule technology is expected to significantly strengthen the product life-cycle management of Pronova BioPharma`s products and has the potential for use both with the Company`s current active pharmaceutical ingredient (`API`), marketed as Omacor in Europe and Lovaza in the United States, as well as in future products under development.
Under the terms of the agreement, FMC will apply its technology to Pronova BioPharma`s products while Pronova BioPharma will be responsible for the clinical development and for securing regulatory approval. Pronova BioPharma plans to initiate clinical trials in early 2009 and launch of the new capsule is anticipated in 2010/2011
FMC`s proprietary capsule technology uses alginate, a marine plant-derived biopolymer, as the main component in the capsule shell. Alginate is gastro-resistant, providing an enteric release profile that delays release of the drug until passage from the stomach into the intestine. The technology also has the benefit of producing a seamless capsule with a significantly thinner shell wall, thus reducing the size of the capsule by approximately 25%. The enteric release profile and smaller size of capsule are expected to result in increased patient compliance.
Watchlist
This is where you can add this news to your personal favourites
Pronova BioPharma and FMC Corporation to develop new alginate-based capsule production
Pronova BioPharma ASA announced that it has entered into a worldwide licence and development agreement with FMC Corporation to develop products using a novel capsule technology. The proprietary alginate-based capsule technology is expected to significantly strengthen the product life-cycle ... more
Bayer CropScience acquires rights to FMC Corporation´s insecticides discovery pipeline
Bayer CropScience AG and FMC Corporation announced that Bayer CropScience has acquired the rights to FMC's insecticides discovery pipeline. The agreement enables Bayer CropScience to discover and commercialize new insecticidal compounds from the discovery pipeline. In return FMC will receiv ... more
Pronova's PRC-4016 enters Phase I clinical trial for treatment of combined dyslipidemia
Pronova BioPharma ASA announced that it has started dosing in a Phase I clinical trial of PRC-4016, a new chemical entity for the treatment of combined dyslipidemia.The First-in-Human clinical trial is a double-blind, placebo-controlled, single and multiple oral dose study to investigate th ... more
Takeda Pharmaceutical Company Limited and Pronova BioPharma ASA jointly announced the top-line results of a pivotal phase 3 clinical trial of TAK-085 (Compendial name: omega-3 acid ethyl esters 90).This is a randomized, double-blind, phase 3 clinical trial to evaluate the efficacy and safe ... more
TAK-085 for the treatment of hypertriglyceridemia entered into phase 3 clinical programs
Takeda Pharmaceutical Company Limited and Pronova BioPharma ASA announced that the advancement of TAK-085 (Compendial name: omega-3 acid ethyl esters 90 (Ph. Eur.)) for the treatment of hypertriglyceridemia into phase 3 clinical programs in Japan. Takeda and Pronova entered into a license ... more
Pronova BioPharma (previously Pronova Biocare) is a global leader in the research, development and manufacture of marine-originated omega-3 derived pharmaceutical products. Pronova BioPharma’s first commercialised product is branded as Omacor in a number of countries throughout Europe and A ... more
About CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2012 CHEMIE.DE Information Service GmbH, All rights reserved
